Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.61 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.61 |
| ▸ | IP6K2 | Q9UHH9 | 3/20 | 0.61 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.61 |
| ▸ | KDM1A | O60341 | 1/20 | 0.61 |
| ▸ | XDH | P47989 | 1/20 | 0.61 |
| ▸ | IPMK | Q8NFU5 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | PLG | P00747 | 1/20 | 0.57 |
| ▸ | FLT3 | P36888 | 2/20 | 0.57 |
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3188009 | 0.87 | CYP1B1 (0.80) | CYP1B1CYP1A1CYP1A2IP6K2ABCC1 | |
| SCHEMBL3185003 | 0.86 | MAOB (0.62) | CYP1B1CYP1A1CYP1A2IP6K2XDH | |
| SCHEMBL15245959 | 0.84 | FLT3 (0.74) | CYP1B1CYP1A1CYP1A2IP6K2ABCC1 | |
| SCHEMBL3184968 | 0.84 | PPARG (0.62) | MAPTMEN1ALDH1A1KMT2AMAOB | |
| SCHEMBL24882669 | 0.81 | EGFR (0.78) | CYP1B1CYP1A1CYP1A2IP6K2XDH | |
| SCHEMBL7773350 | 0.81 | MAOA (0.60) | CYP1B1CYP1A1CYP1A2IP6K2ABCC1 | |
| SCHEMBL1421382 | 0.79 | CYP1B1 (0.86) | CYP1B1CYP1A1CYP1A2IP6K2ABCC1 | |
| SCHEMBL29845342 | 0.79 | CYP1B1 (0.86) | CYP1B1CYP1A1CYP1A2IP6K2ABCC1 | |
| SCHEMBL26117114 | 0.79 | CYP1B1 (0.86) | CYP1B1CYP1A1CYP1A2IP6K2ABCC1 | |
| SCHEMBL7773355 | 0.78 | QPCT (0.53) | CYP1B1CYP1A1CYP1A2IP6K2ABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103965173-A | Compounds and methods for treating estrogen receptor-related disorders | HENOGEN PHARMA GROUP LTD | 2014-08-06 | — | — | CN | disclosed |
| CN-103965172-A | Compounds and methods for treating estrogen receptor-related disorders | SHENOGEN PHARMA GROUP LTD | 2014-08-06 | — | — | CN | disclosed |
| CN-102018698-B | Compounds and methods for treating estrogen receptor-related disorders | SHENOGEN PHARMA GROUP LTD | 2014-07-02 | — | — | CN | disclosed |
| CN-103755673-A | Compounds and methods for treating estrogen receptor-related disorders | SHENOGEN PHARMA GROUP LTD | 2014-04-30 | — | — | CN | disclosed |
| EP-2262366-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | Shenogen Pharma Group Ltd. (CN) | 2010-12-22 | — | — | EP | disclosed |
| US-20100016352-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | SHENOGEN PHARMA GROUP LTD. (CN) | 2010-01-21 | — | — | US | disclosed |
| US-20100016352-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | SHENOGEN PHARMA GROUP LTD. (CN) | 2010-01-21 | — | — | US | disclosed |
| US-20100016352-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | SHENOGEN PHARMA GROUP LTD. (CN) | 2010-01-21 | — | — | US | disclosed |
| WO-2009129372-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | SHENOGEN PHARMA GROUP LTD. (CN) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016352-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | ESR2, ESR1, ESRRB | CYP1B1 2239/4885CYP1A1 1604/4885CYP1A2 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.